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Although periodic cardiac stress testing is commonly used to screen patients on the waiting
list for kidney transplantation for ischemic heart disease, there is little evidence to support this
practice. We hypothesized that cardiac stress testing in the 18 months prior to kidney trans-
plantation would not reduce postoperative death, total myocardial infarction (MI) or fatal MI.
Methods
Using the United States Renal Data System, we identified ESRD patients�40 years old with
primary Medicare insurance who received their first kidney transplant between 7/1/2006 and
11/31/2013. Propensity matching created a 1:1 matched sample of patients with and without
stress testing in the 18 months prior to kidney transplantation. The outcomes of interest were
death, total (fatal and nonfatal) MI or fatal MI within 30 days of kidney transplantation.
Results
In the propensity-matched cohort of 17,304 patients, death within 30 days occurred in 72 of
8,652 (0.83%) patients who underwent stress testing and in 65 of 8,652 (0.75%) patients
who did not (OR 1.07; 95% CI: 0.79–1.45; P = 0.66). MI within 30 days occurred in 339
(3.9%) patients who had a stress test and in 333 (3.8%) patients who did not (OR 1.03; 95%
CI: 0.89–1.21; P = 0.68). Fatal MI occurred in 17 (0.20%) patients who underwent stress
testing and 15 (0.17%) patients who did not (OR 0.97; 95% CI: 0.71–1.32; P = 0.84).
Conclusion
Stress testing in the 18 months prior to kidney transplantation is not associated with a reduc-
tion in death, total MI or fatal MI within 30 days of kidney transplantation.
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Introduction
Cardiovascular disease is a major cause of morbidity and mortality for patients with end stage
renal disease (ESRD) on the waiting list for kidney transplantation and is the leading cause of
death after kidney transplantation [1–5]. Thus, reducing cardiovascular mortality after kidney
transplantation is critically important as donor kidneys are a limited resource that should not be
allocated to patients who are at high risk of potentially fatal perioperative cardiovascular events.
Because patients with ESRD have higher rates of cardiovascular disease than the general
population, especially ischemic heart disease, screening for ischemia prior to placing patients
on the transplant waiting list is performed on most adult patients [6]. Patients without ische-
mia and other contraindications to transplant are placed on the waiting list. Patients with
ischemia are commonly referred for coronary angiography and, if obstructive coronary artery
disease is present, undergo revascularization with percutaneous coronary intervention (PCI)
or coronary artery bypass graft surgery (CABG) after which they are placed on the waiting list.
Patients with extensive disease that is not amenable to revascularization are usually excluded
from consideration of transplant and never placed on the waiting list [7].
Since the timing of donor availability and transplant surgery is unpredictable, asymptomatic
patients with ESRD who have already been screened for ischemia prior to placement on the wait-
ing list commonly undergo stress testing [6] to identify and revascularize those who have devel-
oped ischemia since their initial screening for transplant candidacy. One common strategy is to
perform annual stress tests while the patient is on the waiting list. However, the lack of clinical evi-
dence supporting subsequent stress testing in patients already evaluated for ischemia prior to
placement on the waiting list for kidney transplant has led to varying consensus recommendations
and considerable practice variation across transplant centers [8]. Given that in other clinical set-
tings there is no evidence that assessing for ischemia or revascularization in asymptomatic patients
pre-operatively improves post-operative outcomes, we hypothesized that surveillance of patients
with ESRD who are on the waiting list for kidney transplantation with cardiac stress testing in the
18 months prior to surgery would not be associated with a reduction in perioperative (30-day)
death, total (fatal and nonfatal) myocardial infarction (MI) or fatal MI.
Methods
Data source
Data on patients undergoing renal transplantation were obtained from the USRDS (United
States Renal Data System) database. The USRDS is a comprehensive data set that includes
information on all patients in the United States who develop ESRD and who require renal
replacement therapy, either dialysis or renal transplantation. The USRDS is funded by the
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The USRDS
includes International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-
9-CM) diagnosis and procedure codes, and Current Procedural Terminology, 4th Edition
(CPT-4) codes for Medicare services and transplant information from the United Network for
Organ Sharing (UNOS).
Study population
The study population included ESRD patients�40 years of age who underwent their first kid-
ney transplant between 7/1/2006 and 11/31/2013. The study population was limited to patients
who were insured by Medicare parts A and B for at least 18 months prior to kidney transplan-
tation. Patients were excluded if no claims were made in the 18 months prior to transplant sur-
gery. Stress tests were identified from ICD-9-CM or CPT-4 codes and included exercise and
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pharmacologic stress. To eliminate patients who may have undergone coronary angiography
instead of stress testing as well as those with active ischemic heart disease, individuals were
excluded if coronary angiography, PCI or CABG without stress testing or prior to stress testing
were performed in the 18 months prior to transplantation.
Baseline characteristics including age, sex, height, weight, race and comorbidites were
recorded for the entire study population. Comorbidities were recorded using the Elixhauser
comorbidity classification which is a method of categorizing comorbidities based on ICD-
9-CM codes found in administrative data [9]. Missing height and weight data (each <2%)
were imputed using a sequential imputation algorithm. A regression predictive mean match-
ing method was employed; all available data were used when developing regression models for
height and weight imputation.
Primary outcomes of interest included death from any cause within 30 days following renal
transplant surgery, total MI (fatal and nonfatal) within 30 days of surgery or fatal MI within 30
days of surgery. MI was defined by ICD-9-CM codes 410.xx. Fatal MI was defined by an MI
following surgery and death within 30 days of the MI.
Statistics
Comparisons of patient characteristics between those with and without stress testing were per-
formed using Student’s two sample t-test for continuous variables and chi-square test for cate-
gorical data. All non-normal and ordinal data were summarized by median (1st quartile, 3rd
quartile) and compared using Mann-Whitney U-test. A logistic regression model was created
to identify the propensity for stress testing using the following variables: age, sex, transplant
year, race, body mass index (BMI), donor type, primary disease for ESRD, chronic heart fail-
ure, heart valve disease, pulmonary circulation disease, peripheral vascular disease, paralysis,
other neurological disorders, chronic lung disease, diabetes, hypertension, hyperthyroidism,
liver disease, peptic ulcer disease, acquired immune deficiency syndrome, lymphoma, meta-
static cancer, solid tumor without metastasis, rheumatoid arthritis, coagulopathy, fluid and
electrolyte disorders, chronic blood loss anemia, deficiency anemias, psychoses, depression,
history of MI, CAD, pericardial disease, endocarditis, cardiomyopathy, cerebrovascular dis-
ease, drug abuse, alcohol abuse, weight loss, arrhythmia, cardiac arrest/ventricular fibrillation,
tobacco use, lipid metabolism disorder, and transplant center volume. A Greedy matching
algorithm was then used to create a 1:1 propensity score-matched sample. Standardized differ-
ences were calculated to examine covariate balance before and after matching.
Logistic regression analysis was performed to analyze the association between stress testing
and the outcomes of MI, death and fatal MI in the 30-day postoperative period for the total
sample and for the propensity score-matched sample. For the total sample, multivariable mod-
els were created that included all the same variables used to build the propensity score as inde-
pendent adjustment variables. For the propensity score matched sample, a mixed model
approach was used to account for the matching. Results from both the propensity score match-
ing and multivariable regression analyses are provided separately. All models treated center as
a random effect to account for practice variation across transplant facilities. All analyses were
performed using SAS version 9.3. Two authors (MJS, EN) had full access to the data and
assume responsibility for the integrity of the data and analyses performed.
Results
Study population
A total of 86,837 patients were eligible for analysis (Fig 1). 37,573 patients were excluded for
having insurance other than Medicare parts A and B and 21,448 patients were excluded for
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not having Medicare parts A and B coverage for the entire 18 months prior to transplant.
Twenty-five patients were excluded for not having any insurance claim in the 18 months prior
to transplant. An additional 2,068 patients who did not undergo a stress test but who under-
went angiography, PCI, or CABG in the 18 months prior to transplant were excluded, as were
905 patients who underwent angiography, PCI or CABG prior to their first stress test. After
exclusions, the analytic sample included 24,818 patients of whom 14,811 (59.7%) underwent a
stress test in the 18 months prior to kidney transplantation and 10,007 (39.3%) did not.
Baseline patient characteristics before matching are presented in Table 1. Patients who
underwent stress testing were older (58.3. vs. 56 years, P<0.001), less often female (37.6% vs.
39%, P = 0.029), more often white (57.4% vs. 53.6%, P<0.001), and more often received their
transplanted kidney from a living donor (12% vs. 9.5%, P<0.001). Patients who underwent
stress testing had more risk factors for ischemic heart disease including diabetes (57.2% vs.
47.1%, P<0.001), hypertension (91.6% vs. 81.6%, P<0.001), tobacco use (19.9% vs. 16%, P<
0.001) and dyslipidemia (64.5% vs. 52.2%, P<0.001). Cardiovascular disease was more com-
mon in patients who underwent stress testing including prior MI (7.2% vs. 2.5%, P<0.001),
CAD (42.5% vs. 16.6%, P<0.001), chronic heart failure (24.9% vs. 15.2%, P<0.001), valvular
disease (16.2% vs. 6.2%, P<0.001), arrhythmia (35.7% vs. 21.8%, P<0.001), peripheral vascular
disease (25.8% vs. 16.2%, P<0.001) and cerebrovascular disease (11.2% vs. 6.6%, P<0.001).
Outcomes
Of the 14,811 patients who underwent a stress test, death within 30 days after transplant
occurred in 166 (1.1%) patients who underwent a stress test and in 74 (0.7%) of 10,007 patients
who did not undergo a stress test (P = 0.003). MI within 30 days occurred in 812 (5.5%) of
14,811 patients who underwent stress testing and in 355 (3.5%) of the 10,007 patients who did
Fig 1. Flow diagram of study population. ESRD, end stage renal disease; PCI, percutaneous coronary intervention;
CABG, coronary artery bypass graft surgery.
https://doi.org/10.1371/journal.pone.0211161.g001
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Transplant year, No. (%) < .001
2006 1577 (6.4%) 593 (5.9%) 984 (6.6%)
2007 3125 (12.6%) 1200 (12.0%) 1925 (13.0%)
2008 3183 (12.8%) 1237 (12.4%) 1946 (13.1%)
2009 3335 (13.4%) 1294 (12.9%) 2041 (13.8%)
2010 3346 (13.5%) 1354 (13.5%) 1992 (13.4%)
2011 3496 (14.1%) 1454 (14.5%) 2042 (13.8%)
2012 3391 (13.7%) 1411 (14.1%) 1980 (13.4%)
2013 3365 (13.6%) 1464 (14.6%) 1901 (12.8%)
Recipient Age at Transplant Time 57.34 ± 9.7 56.00 ± 9.7 58.25 ± 9.6 < .001
Female, No. (%) 9469 (38.2%) 3900 (39.0%) 5569 (37.6%) 0.029
Race, No. (%) < .001
Black 8929 (36.0%) 3833 (38.3%) 5096 (34.4%)
White 13859 (55.8%) 5360 (53.6%) 8499 (57.4%)
Other/Multi-racial 2030 (8.2%) 814 (8.1%) 1216 (8.2%)
Height (m) 1.70 ± 0.1 1.70 ± 0.1 1.70 ± 0.1 0.93
Weight (kg) 81.48 ± 18.3 81.37 ± 18.4 81.55 ± 18.2 0.46
Body mass index 28.14 ± 5.4 28.10 ± 5.4 28.17 ± 5.4 0.34
Transplant hospitalization duration in days, median (1st quartile, 3rd quartile) 6.0 (0.0, 522.0) 6.0 (0.0, 522.0) 6.0 (0.0, 505.0) < .001
Donor type, No. (%) < .001
Cadaveric/Unknown 22086 (89.0%) 9056 (90.5%) 13030 (88.0%)
Living 2732 (11.0%) 951 (9.5%) 1781 (12.0%)
Number of transplants performed at facility, median (1st quartile, 3rd quartile) 107.0 (1.0, 385.0) 100.0 (1.0, 385.0) 113.0 (1.0, 385.0) < .001
Primary cause of end stage renal disease, No. (%) < .001
Diabetes 8821 (35.5%) 3091 (30.9%) 5730 (38.7%)
Hypertension 6772 (27.3%) 2893 (28.9%) 3879 (26.2%)
Glomerulonephritis 4635 (18.7%) 2060 (20.6%) 2575 (17.4%)
Cystic kidney/Other urologic 2053 (8.3%) 875 (8.7%) 1178 (8.0%)
Other 2537 (10.2%) 1088 (10.9%) 1449 (9.8%)
Risk Factors
Diabetes, No. (%) 13187 (53.1%) 4709 (47.1%) 8478 (57.2%) < .001
Hypertension, No. (%) 21634 (87.2%) 8062 (80.6%) 13572 (91.6%) < .001
Disorders of lipid metabolism, No. (%) 14779 (59.5%) 5228 (52.2%) 9551 (64.5%) < .001
Tobacco use, No. (%) 4552 (18.3%) 1600 (16.0%) 2952 (19.9%) < .001
Cardiovascular History
Coronary artery disease, No. (%) 7960 (32.1%) 1660 (16.6%) 6300 (42.5%) < .001
History of myocardial infarction, No. (%) 1318 (5.3%) 253 (2.5%) 1065 (7.2%) < .001
Congestive heart failure, No. (%) 5209 (21.0%) 1517 (15.2%) 3692 (24.9%) < .001
Cardiomyopathy, No. (%) 1682 (6.8%) 425 (4.2%) 1257 (8.5%) < .001
Valvular disease, No. (%) 3018 (12.2%) 621 (6.2%) 2397 (16.2%) < .001
Arrhythmia/Conduction disease, No. (%) 7479 (30.1%) 2186 (21.8%) 5293 (35.7%) < .001
Cardiac arrest/Ventricular fibrillation, No. (%) 243 (1.0%) 62 (0.6%) 181 (1.2%) < .001
Pericardial disease, No. (%) 475 (1.9%) 138 (1.4%) 337 (2.3%) < .001
Peripheral vascular disease, No. (%) 5437 (21.9%) 1618 (16.2%) 3819 (25.8%) < .001
Cerebrovascular disease, No. (%) 2311 (9.3%) 658 (6.6%) 1653 (11.2%) < .001
Comorbidities
(Continued)
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not undergo a stress test (P<0.001). On multivariable analysis, stress testing prior to kidney
transplantation was not associated with a reduced risk of death (OR, 1.21; 95% CI: 0.90–1.62;
P = 0.21), MI (OR, 1.09; 95% CI: 0.94–1.26; P = 0.25) or total MI (OR, 1.10; 95% CI: 0.61–2.00;
P = 0.74).
Propensity-matched patients
A total of 17,304 patients were propensity-matched in a 1:1 ratio. Baseline patient characteris-
tics after matching are presented in Table 2. Propensity matching eliminated differences in
demographics, risk factors and comorbidities between groups (Fig 2). Of propensity-matched
patients who underwent stress testing, 1,149 (13.3%) subsequently underwent coronary angi-
ography, 145 (1.7%) underwent PCI and 35 (0.4%) underwent CABG.
Outcomes for the propensity-matched cohort are presented in Table 3. Death within 30
days occurred in 72 (0.83%) patients who had a stress test and in 65 (0.75%) patients who did
not have a stress test (OR 1.07; 95% CI: 0.79–1.45; P = 0.66). MI within 30 days occurred in
339 (3.9%) patients who had a stress test and in 333 (3.8%) patients who did not (OR 1.03; 95%
CI: 0.89–1.21; P = 0.68). Fatal MI occurred in 17 patients who underwent a stress test (0.20%)
and in 15 patients who did not (0.17%) (OR 0.968; 95% CI: 0.71–1.32; P = 0.84). In total, of the
672 patients who developed an MI, 32 (4.8%) subsequently died within 30 days. Of the 137
patients who died within 30 days of their transplant, only 32 (23%) had suffered an MI.
Discussion
The significant findings of this observational cohort study of cardiac stress testing in ESRD
patients after placement on the waiting list but prior to kidney transplantation are two-fold.
First, patients who are placed on the waiting list for kidney transplantation are at relatively low
risk of perioperative death, MI or fatal MI. Second, and most importantly, cardiac stress testing
in the 18 months prior to renal transplantation is not independently associated with a reduc-
tion in 30-day death, MI or fatal MI after adjustment for differences in demographics and
comorbidities by logistic regression and propensity matching techniques.
The role of preoperative cardiovascular risk assessment is to assist the patient and health
care providers in weighing the benefits and risks of surgery. Given the unpredictability of
donor availability and the timing of transplant surgery, many patients on the kidney transplant
waiting list undergo a version of preoperative risk assessment whereby they undergo periodic
stress tests to monitor them for the development of ischemia. That the stress tests were
intended for screening as opposed to investigation of ischemic symptoms is supported by the
low rate of coronary angiography (13.3%) and revascularization (2.1%) in the propensity
matched cohort. Screening stress tests are not recommended in other preoperative patient
populations. The 2014 American College of Cardiology/American Heart Association (ACC/
AHA) guideline on perioperative cardiovascular evaluation and management of patients
undergoing noncardiac surgery recommends pre-operative cardiac evaluation, including









Chronic pulmonary disease, No. (%) 3276 (13.2%) 1119 (11.2%) 2157 (14.6%) < .001
Liver disease, No. (%) 2012 (8.1%) 664 (6.6%) 1348 (9.1%) < .001
Hypothyroidism, No. (%) 3496 (14.1%) 1263 (12.6%) 2233 (15.1%) < .001
https://doi.org/10.1371/journal.pone.0211161.t001
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Transplant year, No. (%) 0.45
2006 1045 (6.0%) 534 (6.2%) 511 (5.9%)
2007 2085 (12.0%) 1064 (12.3%) 1021 (11.8%)
2008 2172 (12.6%) 1092 (12.6%) 1080 (12.5%)
2009 2232 (12.9%) 1116 (12.9%) 1116 (12.9%)
2010 2366 (13.7%) 1173 (13.6%) 1193 (13.8%)
2011 2502 (14.5%) 1243 (14.4%) 1259 (14.6%)
2012 2422 (14.0%) 1198 (13.8%) 1224 (14.1%)
2013 2480 (14.3%) 1232 (14.2%) 1248 (14.4%)
Recipient Age at Transplant Time 56.58 ± 9.5 56.59 ± 9.6 56.57 ± 9.5 0.89
Female, No. (%) 6846 (39.6%) 3440 (39.8%) 3406 (39.4%) 0.59
Race, No. (%) 0.16
Black 6526 (37.7%) 3221 (37.2%) 3305 (38.2%)
White 9384 (54.2%) 4711 (54.4%) 4673 (54.0%)
Other/Multi-racial 1394 (8.1%) 720 (8.3%) 674 (7.8%)
Height (m) 1.70 ± 0.1 1.70 ± 0.1 1.70 ± 0.1 0.91
Weight (kg) 81.59 ± 18.4 81.53 ± 18.3 81.65 ± 18.6 0.65
Body mass index 28.21 ± 5.4 28.19 ± 5.4 28.22 ± 5.4 0.73
Transplant hospitalization duration in days, median (1st quartile, 3rd quartile) 6.0 (0.0, 522.0) 6.0 (0.0, 522.0) 6.0 (0.0, 258.0) 0.69
Donor type, No. (%) 0.49
Cadaveric/Unknown 15595 (90.1%) 7784 (90.0%) 7811 (90.3%)
Living 1709 (9.9%) 868 (10.0%) 841 (9.7%)
Number of transplants performed at facility, median (1st quartile, 3rd quartile) 106.0 (1.0, 385.0) 103.0 (1.0, 385.0) 108.0 (1.0, 385.0) 0.22
Primary cause of end stage renal disease, No. (%) 0.86
Diabetes 5767 (33.3%) 2864 (33.1%) 2903 (33.6%)
Hypertension 4889 (28.3%) 2440 (28.2%) 2449 (28.3%)
Glomerulonephritis 3333 (19.3%) 1679 (19.4%) 1654 (19.1%)
Cystic kidney/Other urologic 1503 (8.7%) 763 (8.8%) 740 (8.6%)
Other 1812 (10.5%) 906 (10.5%) 906 (10.5%)
Risk Factors
Diabetes, No. (%) 8758 (50.6%) 4367 (50.5%) 4391 (50.8%) 0.70
Hypertension, No. (%) 15072 (87.1%) 7535 (87.1%) 7537 (87.1%) 0.95
Disorders of lipid metabolism, No. (%) 9739 (56.3%) 4847 (56.0%) 4892 (56.5%) 0.46
Tobacco use, No. (%) 3010 (17.4%) 1483 (17.1%) 1527 (17.6%) 0.37
Cardiovascular History
Coronary artery disease, No. (%) 3365 (19.4%) 1659 (19.2%) 1706 (19.7%) 0.07
History of myocardial infarction, No. (%) 534 (3.1%) 251 (2.9%) 283 (3.3%) 0.13
Congestive heart failure, No. (%) 2947 (17.0%) 1459 (16.9%) 1488 (17.2%) 0.54
Cardiomyopathy, No. (%) 834 (4.8%) 411 (4.8%) 423 (4.9%) 0.67
Valvular disease, No. (%) 1253 (7.2%) 618 (7.1%) 635 (7.3%) 0.56
Arrhythmia/Conduction disease, No. (%) 4266 (24.7%) 2142 (24.8%) 2124 (24.5%) 0.72
Cardiac arrest/Ventricular fibrillation, No. (%) 127 (0.7%) 60 (0.7%) 67 (0.8%) 0.53
Pericardial disease, No. (%) 271 (1.6%) 136 (1.6%) 135 (1.6%) 0.95
Peripheral vascular disease, No. (%) 3117 (18.0%) 1562 (18.1%) 1555 (18.0%) 0.88
Cerebrovascular disease, No. (%) 1265 (7.3%) 634 (7.3%) 631 (7.3%) 0.93
Comorbidities
(Continued)
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in general, cardiac stress testing in anticipation of surgery should not be performed. However,
ESRD is considered a significant risk factor for CAD and such patients undergoing kidney
transplantation are considered at increased risk for perioperative adverse cardiac events. A
2016 study of United States hospital admissions from 2004 to 2013 found a 3% incidence of
major adverse cardiovascular and cerebrovascular events (in-hospital, all-cause death, acute
MI, or acute ischemic stroke) in the postoperative period [11]. These events were most com-
mon after vascular (7.7%), thoracic (6.5%), and transplant surgery (6.3%). In recognition of
the increased risk of patients undergoing kidney transplant surgery, a 2012 AHA Consensus
Statement, in the absence of any high-quality data, indicated that stress testing could be con-
sidered in kidney transplantation candidates with no active cardiac conditions based on the
presence of multiple CAD risk factors regardless of functional status (Class IIb, Level of Evi-
dence C) [2]. However, the current results suggest that patients with ESRD who have been









Chronic pulmonary disease, No. (%) 2078 (12.0%) 1038 (12.0%) 1040 (12.0%) 0.96
Liver disease, No. (%) 1259 (7.3%) 627 (7.2%) 632 (7.3%) 0.88
Hypothyroidism, No. (%) 2325 (13.4%) 1166 (13.5%) 1159 (13.4%) 0.88
https://doi.org/10.1371/journal.pone.0211161.t002
Fig 2. Covariate balance before and after propensity score matching. CAD, coronary artery disease; CHF,
congestive heart failure; PVC, peripheral vascular disease; MI, myocardial infarction; DM, diabetes mellitus; CVD,
cerebrovascular disease; Circ, circulation; VF, ventricular fibrillation; BMI, body mass index; AIDS, acquired
immunodeficiency syndrome.
https://doi.org/10.1371/journal.pone.0211161.g002
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transplantation are not at particularly high risk, perhaps because the highest risk patients are
removed from consideration of transplant during the initial screening process. In the Coro-
nary Artery Revascularization Prophylaxis (CARP) trial of patients who underwent surgery for
peripheral arterial or aortic disease, 30-day mortality was 3.2% [12] as opposed to 0.8% in the
propensity-matched cohort and 1.1% in the stress testing arm of the overall cohort in the cur-
rent study. Furthermore, the fatal MI rate of 0.2% makes it highly unlikely that any screening
strategy could be shown to reduce that rate further.
Many studies have demonstrated that stress testing can further stratify the risk of adverse
perioperative events [10–21]. Although there is a clear relationship between the degree of myo-
cardial ischemia detected and prognosis, there is no evidence that prophylactic revasculariza-
tion prior to surgery improves outcomes [1, 22–30]. However, it is recommended that ESRD
patients with ischemia on stress testing be referred for coronary angiography and revasculari-
zation, if technically feasible, to maintain their candidacy for transplant [31]. Data from CARP
indicates that prophylactic revascularization does not improve outcomes in a vascular surgery
population at 4-fold greater risk of death than ESRD patients undergoing kidney transplanta-
tion. In that randomized, controlled trial, PCI was performed in 59% and CABG was per-
formed in 41% of patients assigned to prophylactic revascularization. At 2.7 years of follow-up,
mortality in the revascularization group was 22% versus 23% in the no-revascularization
group (relative risk, 0.98; 95% confidence interval, 0.70 to 1.37; P = 0.92). Within 30 days of
the vascular operation, 3.1% of patients assigned to revascularization and 3.4% of patients not
assigned to revascularization died (P = 0.87), whereas MI occurred in 12% of the revasculariza-
tion group and 14% of the non-revascularization group (P = 0.37) [12].
The only prospective, randomized data on pre-operative revascularization in ESRD patients
awaiting transplant comes from the 1992 study by Manske et al. who randomly assigned 31
transplantation candidates with insulin-dependent diabetes mellitus and CAD (>75% steno-
sis) to revascularization or medical therapy with a calcium channel blocker and aspirin [32].
Ultimately, 10 of 13 medically managed and 2 of 13 revascularized patients experienced the
composite endpoint consisting of unstable angina, MI or cardiac death. Given the small sample
size of exclusively diabetic patients, the high event rate among the medically managed group
and advances that have occurred in the medical management of diabetes and ischemic heart
disease, including the use of angiotensin-converting enzyme inhibitors and statins, the find-
ings of this study are no longer applicable to contemporary practice.
There are several limitations of this study. First, although our list of confounders was exten-
sive, propensity analyses cannot account for selection bias related to unmeasured characteris-
tics. It should be noted however that a randomized clinical trial is unlikely to be performed to
address the value of preoperative stress testing because the low event rates would require sam-
ple sizes too large to be feasible. Second, this study is based on administrative data including
ICD codes that were designed for reimbursement, not clinical phenotyping. Third, administra-
tive coding for MI does not distinguish between type I (plaque rupture) and type II (supply-
demand mismatch) MI. These different types of MI are approached with different diagnostic
and therapeutic strategies and have different prognostic implications that may influence the





Odds Ratio (stress vs. no stress) 95% Confidence Interval P value
Death within 30 days after transplant 72 (0.83%) 65 (0.75%) 1.07 (0.79, 1.45) 0.66
Acute myocardial infarction within 30 days after transplant 339 (3.9%) 333 (3.8%) 1.03 (0.89, 1.21) 0.68
Fatal myocardial infarction 17 (0.20%) 15 (0.17%) 0.97 (0.71, 1.32) 0.84
https://doi.org/10.1371/journal.pone.0211161.t003
Cardiac stress testing prior to kidney transplantation
PLOS ONE | https://doi.org/10.1371/journal.pone.0211161 February 1, 2019 9 / 12
results of this study. In addition, there was no uniform practice to screen patients for the devel-
opment of postoperative MI. Fourth, we cannot determine how many patients underwent
stress testing during screening for placement on the waiting list and were never listed for trans-
plant due to detection of extensive CAD. However, our intention was specifically to evaluate
the role of stress testing after listing and not during the evaluation process for placement on
the waiting list. In addition, since this data set does not provide specific reasons for removal
from the waiting list, we cannot ascertain if the results of surveillance stress testing led to the
removal of any patients from the waiting list. Finally, since follow-up was limited to 30 days,
the conventionally defined perioperative period, the possibility of late benefit related to stress
testing cannot be excluded.
In conclusion, the routine performance of cardiac stress tests on ESRD patients in the 18
months prior to kidney transplantation is not associated with a reduction in postoperative
death, MI or fatal MI. The use of routine cardiac stress tests in this population should be recon-
sidered until a clinical benefit is demonstrated in randomized, controlled trials.
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